Treating resistant prostate cancer by depriving a key hormone of its 'co-pilot'

Blocking the enzyme CDK7 could be a new way to overcome metastatic castration-resistant prostate cancer, scientists at the University of Pennsylvania have found. Carrick Therapeutics is planning clinical testing of its CDK7 inhibitor, CT7001.